Hays J T, Mahmarian J J, Cochran A J, Verani M S
Department of Medicine, Baylor College of Medicine, Houston, Texas.
J Am Coll Cardiol. 1993 Jun;21(7):1583-90. doi: 10.1016/0735-1097(93)90372-8.
The aim of this study was to assess the feasibility, safety and diagnostic accuracy of a high dose dobutamine infusion in conjunction with thallium-201 single-photon emission computed tomography in 144 patients (72 men and 72 women with a mean age of 65 +/- 10 years) unable to perform exercise or pharmacologic vasodilator stress testing.
Dobutamine increases myocardial oxygen consumption by increasing heart rate, contractility and arterial blood pressure. In addition, it causes myocardial blood flow heterogeneity and thus may be a useful stress for noninvasive detection of coronary artery disease.
Dobutamine was administered intravenously at incremental doses of 5, 10, 20, 30 and up to 40 micrograms/kg per min at 3-min intervals. After 1 min of the maximal dose, 3 mCi of thallium-201 was injected and the infusion was continued for an additional 2 min. Thallium-201 tomography was performed 5 to 10 min after termination of the infusion and 4 h later. The images were visually assessed for the presence and vascular location of perfusion defects and the extent of thallium redistribution. Coronary angiography was performed in 84 patients, with a > 50% stenosis considered significant.
Dobutamine significantly (p = 0.0001) increased the heart rate (from 75 +/- 14 beats/min to 120 +/- 23 beats/min), systolic blood pressure (from 136 +/- 23 mm Hg to 148 +/- 35 mm Hg) and the rate-pressure product (from 10,144 +/- 2,517 to 17,858 +/- 4,349) from baseline to peak infusion rate, respectively. Most patients (75%) experienced side effects during the infusion, but 74% tolerated a dobutamine dose of 40 micrograms/kg per min and 97% a dose of 30 micrograms/kg per min. The more common side effects were typical (26%) and atypical (5%) chest pain, palpitation (29%), flushing (14%), headache (14%) and dyspnea (14%). The overall sensitivity of dobutamine tomography was 86% in the patients who underwent coronary angiography and 84% in those with single-vessel, 82% in those with double-vessel and 100% in those with triple-vessel disease. Seventy-eight percent of vessels with severe (> or = 70%) stenoses were identified with dobutamine tomography. The specificity of dobutamine tomography was 90% for patients and 86% for individual vessels.
A high dose dobutamine infusion in conjunction with thallium tomography appears to be a well tolerated and accurate method for diagnosing coronary artery disease in patients unable to perform exercise or vasodilator pharmacologic stress testing.
本研究旨在评估大剂量多巴酚丁胺静脉输注联合铊 - 201单光子发射计算机断层扫描在144例(72例男性和72例女性,平均年龄65±10岁)无法进行运动或药物血管扩张剂负荷试验的患者中的可行性、安全性及诊断准确性。
多巴酚丁胺通过增加心率、心肌收缩力和动脉血压来增加心肌耗氧量。此外,它会导致心肌血流不均一性,因此可能是用于无创检测冠状动脉疾病的一种有用的负荷方法。
以递增剂量静脉注射多巴酚丁胺,剂量分别为每分钟5、10、20、30直至40微克/千克,每隔3分钟递增一次。在达到最大剂量1分钟后,注射3毫居里的铊 - 201,并继续输注2分钟。在输注结束后5至10分钟以及4小时后进行铊 - 201断层扫描。对图像进行视觉评估,以确定灌注缺损的存在、血管位置以及铊再分布的程度。84例患者接受了冠状动脉造影,狭窄>50%被视为有意义。
从基线到输注峰值速率,多巴酚丁胺显著(p = 0.0001)增加了心率(从75±14次/分钟增至120±23次/分钟)、收缩压(从136±23毫米汞柱增至148±35毫米汞柱)以及心率血压乘积(从10,144±2,517增至17,858±4,349)。大多数患者(75%)在输注过程中出现副作用,但74%的患者耐受40微克/千克每分钟的多巴酚丁胺剂量,97%的患者耐受30微克/千克每分钟的剂量。较常见的副作用为典型胸痛(26%)和非典型胸痛(5%)、心悸(29%)、潮红(14%)、头痛(14%)和呼吸困难(14%)。在接受冠状动脉造影的患者中,多巴酚丁胺断层扫描的总体敏感性为86%,单支血管病变患者中为84%,双支血管病变患者中为82%,三支血管病变患者中为100%。多巴酚丁胺断层扫描可识别78%的严重(≥70%)狭窄血管。多巴酚丁胺断层扫描对患者的特异性为90%,对单个血管的特异性为86%。
大剂量多巴酚丁胺输注联合铊断层扫描似乎是一种耐受性良好且准确的方法,可以用于诊断无法进行运动或血管扩张剂药物负荷试验的患者的冠状动脉疾病。